To assess the effect of the drug tranexamic acid on the blood loss and rate of blood transfusion by infiltrating it into the joint and by giving it directly into the vein in patients undergoing total knee replacement surgery.

The effect of Intravenous and Intraarticular administration of Tranexamic acid on the Blood loss and Rate of blood transfusion after Total Knee replacement. A Randomized Controlled Study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/01/017105

Enrollment

150

Registered

2019-01-16

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M171- Unilateral primary osteoarthritisof knee

Interventions

Intervention1: TRANEXAMIC ACID: This drug is an anti fibrinolytic used for more than two decades to decrease the blood loss in surgeries.The aim of my study is to compare the effect of the drug on bl

Eligibility

Inclusion criteria

Inclusion criteria: Primary unilateral osteoarthritis of knee joint

Exclusion criteria

Exclusion criteria: Diagnosis other than primary osteoarthritis Previous knee surgery Inflammatory and infectious arthritis Underlying coagulopathy Post traumatic arthritis Patients receiving anticoagulation therapy History of thromboembolic & cardiovascular disease

Design outcomes

Primary

Measure	Time frame
The final outcome will be measured in terms of total blood loss and need for any blood transfusionTimepoint: 2 Time Points .Immediate post operative and 4 weeks post opaerative	—

Secondary

Measure	Time frame
Symptomatic Deep Venous Thrombosis,Wound Complications And InfectionTimepoint: 2 Time points.Immediate post operative and 4 weeks post operative	—

Countries

India

Contacts

Public ContactNissar Ahmad Shah

Ganga Hospital

drrajkumarn@gmail.com9443366258

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026